{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T04:38:52Z","timestamp":1771303132117,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Cardiovascular Research Institute of the University of Vermont"},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Black US adults experience a greater hypertension burden and have lower levels of soluble receptors for advanced glycation end products (sRAGE). sRAGE may reduce inflammation, which is itself a hypertension risk factor. We hypothesized that higher sRAGE levels are associated with a lower risk of incident hypertension in a cohort of Black and White adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The REasons for Geographic and Racial Differences in Stroke (REGARDS) enrolled 30,239 Black and White adults from the contiguous United States in 2003-2007; a second visit occurred in 2013-2016. sRAGE was measured at baseline by ELISA in 4,400 participants attending both visits. Hypertension was defined as BP\u2005&amp;gt;\u2005140\/90 mm Hg or use of antihypertensive medications. Participants with baseline hypertension were excluded. Poisson regression estimated incident hypertension risk ratios (RR) by sRAGE levels, adjusting for confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 1,799 participants without baseline hypertension (mean [SD] age 62 [8] years, 55% females, 25% Black), 46% of Black participants and 31% of White participants developed hypertension. Median sRAGE was lower in Black than White persons (P\u2005&amp;lt;\u20050.0001). Relative to quartile 1, White participants in quartile 4 of sRAGE had a 24% lower risk of incident hypertension (RR 0.76; 95% CI 0.59, 0.96) in a minimally adjusted model, but no differences in a fully adjusted model (0.81; 0.63 to 1.05). There was no association of sRAGE with hypertension in Black participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Higher baseline sRAGE levels were not associated with lower risk of incident hypertension after adjusting for known confounders. Low sRAGE might represent adverse inflammation that drives hypertension rather than being a primary driver of hypertension development itself.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpaf109","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:15:47Z","timestamp":1752502547000},"page":"1088-1095","source":"Crossref","is-referenced-by-count":2,"title":["Soluble Receptor for Advanced Glycation End Products and Incident Hypertension in REGARDS"],"prefix":"10.1093","volume":"38","author":[{"given":"Sarah D R","family":"Krumholz","sequence":"first","affiliation":[{"name":"Larner College of Medicine at the University of Vermont , Burlington, Vermont ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Cushman","sequence":"additional","affiliation":[{"name":"Larner College of Medicine at the University of Vermont , Burlington, Vermont ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nels C","family":"Olson","sequence":"additional","affiliation":[{"name":"Larner College of Medicine at the University of Vermont , Burlington, Vermont ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D Leann","family":"Long","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Science, Wake Forest University School of Medicine , Winston-Salem, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne E","family":"Judd","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia J","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-9597","authenticated-orcid":false,"given":"Timothy B","family":"Plante","sequence":"additional","affiliation":[{"name":"Larner College of Medicine at the University of Vermont , Burlington, Vermont ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2025111618571816000_CIT0001","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","article-title":"2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"2025111618571816000_CIT0002"},{"key":"2025111618571816000_CIT0003","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ajh\/hpaa215","article-title":"C-reactive protein and incident hypertension in Black and White Americans in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Cohort Study","volume":"34","author":"Plante","year":"2021","journal-title":"Am J Hypertens"},{"key":"2025111618571816000_CIT0004","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1161\/HYPERTENSIONAHA.123.22714","article-title":"Cytokines, C-reactive protein, and risk of incident hypertension in the REGARDS Study","volume":"81","author":"Plante","year":"2024","journal-title":"Hypertens Dallas Tex 1979"},{"key":"2025111618571816000_CIT0005","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.metabol.2017.02.008","article-title":"Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults","volume":"70","author":"Brinkley","year":"2017","journal-title":"Metabolism"},{"key":"2025111618571816000_CIT0006","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2017.08.015","article-title":"Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease","volume":"266","author":"Reichert","year":"2017","journal-title":"Atherosclerosis"},{"key":"2025111618571816000_CIT0007","doi-asserted-by":"publisher","first-page":"101958","DOI":"10.1016\/j.redox.2021.101958","article-title":"The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes","volume":"42","author":"Erusalimsky","year":"2021","journal-title":"Redox Biol"},{"key":"2025111618571816000_CIT0008","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.mad.2015.01.001","article-title":"Age and genetic determinants of variation of circulating levels of the receptor for advanced glycation end products (RAGE) in the general human population","volume":"145","author":"Prakash","year":"2015","journal-title":"Mech Ageing Dev"},{"key":"2025111618571816000_CIT0009","doi-asserted-by":"publisher","first-page":"e0128452","DOI":"10.1371\/journal.pone.0128452","article-title":"Genetics of plasma soluble receptor for advanced glycation end-products and cardiovascular outcomes in a community-based population: results from the Atherosclerosis Risk in Communities Study","volume":"10","author":"Maruthur","year":"2015","journal-title":"PLoS One"},{"key":"2025111618571816000_CIT0010","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1177\/1933719114549845","article-title":"Relationship of advanced glycation end products with cardiovascular disease in menopausal women","volume":"22","author":"Pertynska-Marczewska","year":"2015","journal-title":"Reprod Sci"},{"key":"2025111618571816000_CIT0011","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000086678","article-title":"The REasons for geographic and racial differences in stroke study: objectives and design","volume":"25","author":"Howard","year":"2005","journal-title":"Neuroepidemiology"},{"key":"2025111618571816000_CIT0012","doi-asserted-by":"publisher","first-page":"e016482","DOI":"10.1161\/JAHA.120.016482","article-title":"Life\u2019s simple 7 and incident hypertension: the REGARDS Study","volume":"9","author":"Plante","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025111618571816000_CIT0013","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.annepidem.2021.10.010","article-title":"Biomarkers as MEDiators of racial disparities in risk factors (BioMedioR): rationale, study design, and statistical considerations","volume":"66","author":"Long","year":"2022","journal-title":"Ann Epidemiol"},{"key":"2025111618571816000_CIT0014","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertens Dallas Tex 1979"},{"key":"2025111618571816000_CIT0015","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.117.032582","article-title":"Potential US population impact of the 2017 ACC\/AHA high blood pressure guideline","volume":"137","author":"Muntner","year":"2018","journal-title":"Circulation"},{"key":"2025111618571816000_CIT0016","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertens Dallas Tex 1979"},{"key":"2025111618571816000_CIT0017","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2307\/2136404","article-title":"A global measure of perceived stress","volume":"24","author":"Cohen","year":"1983","journal-title":"J Health Soc Behav"},{"key":"2025111618571816000_CIT0018","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials\u2014a practical guide with flowcharts","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2025111618571816000_CIT0019","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-3-319-19425-7_13","article-title":"Ordinal logistic regression","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2015"},{"key":"2025111618571816000_CIT0020","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0037-1598183","article-title":"Do advanced glycation end products and its receptor play a role in pathophysiology of hypertension","volume":"26","author":"Prasad","year":"2017","journal-title":"Int J Angiol Off Publ Int Coll Angiol Inc"},{"key":"2025111618571816000_CIT0021","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/hr.2015.131","article-title":"Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population","volume":"39","author":"Mayer","year":"2016","journal-title":"Hypertens Res"},{"key":"2025111618571816000_CIT0022","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/rheumatology\/kep199","article-title":"Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases","volume":"48","author":"Maillard-Lefebvre","year":"2009","journal-title":"Rheumatology"},{"key":"2025111618571816000_CIT0023","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.3390\/ijms20163942","article-title":"Association between advanced glycation end products, soluble RAGE receptor, and endothelium dysfunction, evaluated by circulating endothelial cells and endothelial progenitor cells in patients with mild and resistant hypertension","volume":"20","author":"Gryszczy\u0144ska","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025111618571816000_CIT0024","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1161\/01.ATV.0000160342.20342.00","article-title":"Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men","volume":"25","author":"Falcone","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025111618571816000_CIT0025","first-page":"187","article-title":"Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients","volume":"18","author":"McNair","year":"2009","journal-title":"Int J Angiol Off Publ Int Coll Angiol Inc"},{"key":"2025111618571816000_CIT0026","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2105\/AJPH.2019.305245","article-title":"The myth of innate racial differences between White and Black people\u2019s bodies: lessons from the 1793 Yellow Fever epidemic in Philadelphia, Pennsylvania","volume":"109","author":"Hogarth","year":"2019","journal-title":"Am J Public Health"},{"key":"2025111618571816000_CIT0027","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2105\/ajph.90.11.1699","article-title":"Why genes don\u2019t count (for racial differences in health)","volume":"90","author":"Goodman","year":"2000","journal-title":"Am J Public Health"},{"key":"2025111618571816000_CIT0028","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jamacardio.2022.2345","article-title":"Age at diagnosis of hypertension by race and ethnicity in the US from 2011 to 2020","volume":"7","author":"Huang","year":"2022","journal-title":"JAMA Cardiol"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaf109\/63843463\/hpaf109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/38\/12\/1088\/63843463\/hpaf109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/38\/12\/1088\/63843463\/hpaf109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T23:57:21Z","timestamp":1763337441000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/38\/12\/1088\/8212080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,7,25]]},"published-print":{"date-parts":[[2025,11,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaf109","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,25]]}}}